Key takeaways
- The TGA says it is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia.
- BPC-157 has been Schedule 4 (prescription only) since 1 June 2024; the October 2026 Poisons Standard also lists TB-500, thymosin beta-4, CJC-1295 and ipamorelin.
- For BPC-157, TB-500 and several growth-hormone peptides, the Poisons Standard says possession without authority is illegal (Appendix D, clause 5).
- The TGA says “research use only” disclaimers do not make supply lawful or permit importation.
- In 2026 the TGA’s peptide actions included public warnings, seizures and infringement notices.
01What does the TGA say about unapproved peptides?
In August 2026 the TGA put the position in one sentence: “It is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia.” Under the Therapeutic Goods Act 1989, peptide products supplied for therapeutic use are regulated as therapeutic goods. Those not included on the Australian Register of Therapeutic Goods (ARTG) are “unapproved”.
The TGA’s April 2026 safety advisory names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products.
The TGA says penalties for breaching the Act include civil penalties of up to $1.82 million per breach for individuals or $18.2 million per breach for corporations, and criminal penalties of up to 7 years’ imprisonment.
Compounding is a narrow exception. The TGA says a compounded good is generally exempt from ARTG inclusion only where it is “dispensed or extemporaneously compounded for a particular person for application to that person”, or compounded in a hospital by a pharmacist for the hospital’s patients. Pharmacists and doctors who fall outside the exemptions in Schedule 8 of the Therapeutic Goods Regulations 1990 generally need a manufacturing licence, the TGA says.
02How does the Poisons Standard treat peptides? Schedule 4 and possession controls
The Poisons Standard decides how a substance may be supplied. Schedule 4 is “Prescription only medicines and prescription animal remedies”.
BPC-157 entered Schedule 4 on 1 June 2024. The TGA’s final decision, published on 22 May 2024, responded to “48 referrals for importation of BPC-157 received by the TGA since 1 July 2022” and aimed to “align the scheduling of BPC-157 with other performance- and image-enhancing substances”. The same decision added it to Appendix D, clause 5: “Poisons for which possession without authority is illegal”.
The current instrument, the Poisons Standard October 2026 (registered 30 September 2026), keeps those entries. Selected peptide entries:
| Substance | Poisons Standard schedule | Appendix D, clause 5: possession without authority is illegal |
|---|---|---|
| BPC-157 | Schedule 4 | Yes |
| TB-500 | Schedule 4 | Yes |
| Thymosin beta-4 | Schedule 4 | Yes |
| CJC-1295 | Schedule 4 | Yes |
| Ipamorelin | Schedule 4 | Yes |
| Growth hormone releasing peptides (GHRPs), including GHRP-6 | Schedule 4 | Yes |
| Melanotan II | Schedule 4 | No |
Many peptides, including Semax, epitalon, MOTS-c and KPV, are not named individually. That does not make them lawful to sell: a product supplied for therapeutic use still needs ARTG inclusion, and group entries in the Standard may apply. We have not assessed each compound against the group entries.
The TGA notes that “state and territory laws may impose additional controls on the sale, supply and possession of unapproved peptide products.”
03How are peptide imports controlled in Australia?
Personal importation. The TGA’s April 2026 advisory says people importing unapproved peptides under the Personal Importation Scheme “must meet all other conditions of the Scheme, including having an appropriate medical authorisation or prescription when required”. Products identified only by codes, or that do not clearly state the active ingredient and strength, “cannot be assessed for lawful importation under the Personal Importation Scheme, and will not be considered for release”. In July 2026 the TGA said it is “increasingly intercepting unlabelled vials at the border”.
Customs permission for hormones. Under regulation 5G of the Customs (Prohibited Imports) Regulations 1956, substances in Schedule 7A may not be imported without written permission. Schedule 7A covers anabolic or androgenic substances, erythropoietin, darbepoetin alfa, gonadotrophins including HCG, and “natural and manufactured growth hormones, including somatropin, somatrem, somatomedins and insulin-like growth factors (not insulins) and growth hormone releasing hormones (somatorelin and synthetic analogues)”. A narrow exception for prescribed medicine carried by a ship or aircraft passenger does not apply to athletes or their support staff.
BPC-157 and TB-500 are not named in Schedule 7A. Their import is controlled through the therapeutic goods and poisons rules above.
04What did the TGA do about peptides in 2026?
In 2026 the TGA’s peptide actions included public warnings, seizures and infringement notices. From its own releases:
| Date | What the TGA did |
|---|---|
| 13 Apr 2026 | Safety advisory on importing, compounding and supplying unapproved peptides: “research use only” disclaimers do not make supply lawful. |
| 10 Jun 2026 | Added unapproved peptide products to its compliance priorities, citing a joint operation with Australian Border Force and Victoria Police that seized peptides, steroids and other products with an estimated street value above $2 million. |
| 20 Jul 2026 | Put promoters and suppliers “on notice”. Manufacture, it said, includes “applying a label to a blank vial”. |
| 17 Aug 2026 | Announced the seizure, with NSW Police, of more than $120,000 of peptide and steroid products allegedly linked to a social media influencer (warrants executed 4 Aug), including retatrutide, CJC-1295 and a combined BPC-157 and TB-500 product. |
| 17 Aug 2026 | Safety advisory: TGA testing found inconsistent amounts of melanotan II in seized nasal sprays. It reported 27 infringement notices, totalling $101,412 and paid in May 2026, issued to a NSW individual for alleged unlawful supply. |
The TGA has also said that “influencers, affiliates, online sellers and anyone else promoting unapproved peptide products may be held accountable for unlawful advertising”.
05Is BPC-157 prohibited in Australian sport?
Sport Integrity Australia describes BPC-157 as “an experimental peptide that is not approved for use by any regulatory agency worldwide”, and lists it under S0, non-approved substances, prohibited at all times. Under the customs rule above, athletes and their support staff cannot rely on the passenger exception for Schedule 7A hormones. Detail: peptides and anti-doping.
06What don’t we know about Australian peptide rules?
State and territory detail. How each jurisdiction enforces the Appendix D possession controls, and what penalties apply, is set by state and territory poisons laws we have not summarised here.
Unnamed peptides. Whether Semax, epitalon, MOTS-c, KPV or GHK-Cu fall under any group entry, or will be scheduled by name, is not something we can tell you from the Standard alone.
Changes are logged in our regulatory changelog. For the other markets, see the US, the UK or the overview.
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.